Is BioNano genomics (bngo) stock breaking down?
Bionano (BNGO) is a life sciences company looking to make an impact in the cytogenetics space – that is in the study of chromosomes. This it is planning to …
What's happening with bngo stock post-earnings?
san diego, march 03, 2022 (globe newswire) -- bionano genomics, inc. (bngo), pioneer of optical genome mapping (ogm) solutions on the saphyr® system and provider of …
How can I get the latest news and ratings for bngo?
Apr 04, 2022 · View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations. Get daily stock ideas top-performing Wall Street analysts.
Why is bngo stock on a wild ride?
Aug 05, 2021 · Bionano Genomics, Inc. (BNGO) stock was dropping in the pre-market today following the announcement of Q2 2021 financial results. BNGO stock saw a downtrend of 3.24% to drop at $3.24 a share at the time of this writing. The stock was also gloomy in the previous trade and went down by 1.01% at closing. Let’s deep dive to explore more of it.
Is BNGO a buy right now?
Those tracked by the Wall Street Journal have BNGO rated as a consensus “buy” with an average $12 price target.Dec 14, 2021
Is BNGO expected to rise?
Bionano Genomics Inc (NASDAQ:BNGO) The 4 analysts offering 12-month price forecasts for Bionano Genomics Inc have a median target of 7.50, with a high estimate of 14.00 and a low estimate of 6.00. The median estimate represents a +262.32% increase from the last price of 2.07.
Is BNGO buy or sell?
Bionano Genomics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is BNGO a US stock?
BNGO:USNASDAQ CM. Bionano Genomics Inc.
Who owns Bionano genomics?
Top 10 Owners of Bionano Genomics IncStockholderStakeShares ownedBlackRock Fund Advisors5.74%16,609,007The Vanguard Group, Inc.4.86%14,064,639SSgA Funds Management, Inc.2.49%7,198,880Geode Capital Management LLC1.63%4,714,8836 more rows
Is BNGO a pump and dump?
BNGO stock has suffered at the hands of a Ritalin-using pump and dump scheme making waves in 2021.May 7, 2021
Does BNGO have FDA approval?
The Food and Drug Administration has not yet approved the device for use as a medical diagnostic tool in the U.S. However, healthcare entities can still use it for research purposes. The lack of FDA approval has also not hindered sales of the Saphyr in other countries.Jun 8, 2021
What type of stock is BNGO?
Common Stock (BNGO)
Does Ark hold BNGO?
Does ARK Invest in BNGO: The Bottom Line. At this time, ARK does not invest in BNGO. With that said, the company does appear to have some promise in its own right. Like all speculative small-cap companies, Bionano Genomics is a risky stock to own.
Is BNGO in Russell?
(Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstitution.Jun 28, 2021
What is the short interest in BNGO?
Bionano Genomics currently has a short interest ratio of 5.0.
How many shares does BNGO have?
83,218,166 sharesBioNano Genomics Inc (US:BNGO) has 292 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 83,218,166 shares.
When is Bionano 2021?
What is the Saphyr system?
SAN DIEGO, July 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the 2021 Ladenburg Thalmann Healthcare Conference being held July 13-14, 2021. Erik Holmlin, PhD, Bionano’s Chief Executive Officer, will present a company overview on July 13, 2021 at 4:30pm EDT. The presentation will be available to view on the Events page in the Investors section of Bionano’s website and at Ladenburg Thalmann Healthcare Conferenc
Is Bionano a member of Russell 2000?
(Nasdaq: BNGO) announced significant progress in China with the adoption of its Saphyr® System for optical genome mapping (OGM) by WeHealth Shanghai, a leading provider of genome analysis services in reproductive health. The adoption was announced at the Structural Variation Symposium in Shanghai, organized with support from the Shanghai Society of Genetics. WeHealth announced the launch of its complete genome-analysis offering
Bionano Genomics Media Sentiment
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that it was added as a member of the US small-cap Russell 2000® Index, effective after the US market opens on Monday, June 28, 2021, as part of the 2021 Russell indexes reconstitution. Membership in the Russell 2000® Index, which remains in place for one year, is based on membership in the broad-market Russell 3000® Index. The stock also was automatically added to the appropriate growth and value i
Media Coverage
Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.
Bionano Genomics (NASDAQ BNGO) News Headlines Today
We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.
Second Quarter 2021 Financial Results
Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm.
Balance Sheet of BNGO stock
BNGO stock suffered a $0.06 per share quarterly loss in the reported quarter. This is above than Zacks Consensus Estimate of loss of $0.05 per share.
Upcoming Milestones of BNGO stock
At the end of June 30, 2021, BNGO stock reported $333 million in cash and cash equivalents. These were $38.4 million by the end of December 2020. The equity raise completed in January 2021 is the main reason behind this increase.
Conclusion
Bionano stock expects Commercial release of prenatal assays in the third quarter of 2021. pediatric assays menu expansion is also anticipated in the third quarter.
Signals & Forecast
BNGO stock is falling despite increased revenue in second-quarter 2021 as compared to the same prior-year quarter. However, one thing is to note that its earnings surprise is -20% and quarterly loss is above the Zacks Consensus Estimate. The stock is progressing with time and continuing to conduct clinical studies which is a good sign.
Support, Risk & Stop-loss
There are mixed signals in the stock today. The BioNano Genomics Inc. stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is BioNano Genomics Inc. stock A Buy?
BioNano Genomics Inc. finds support from accumulated volume at $5.55 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
The Reddit Effect Strikes Again
BioNano Genomics Inc. holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
Bottom Line on BNGO Stock
One of the big news stories of 2021 has been the Reddit effect. Retail investors have been using the platform to drive up the prices of many stocks that were previously struggling and attracting short-sellers.
What happened
BioNano doesn’t get the degree of analyst coverage that headline-grabbing biotech companies have over the past year. CNN Money is following just four investment analysts that cover BNGO stock.
So what
Shares of Bionano Genomics (NASDAQ: BNGO) fell on Wednesday after the genome-analysis company announced the pricing of its public stock offering. As of 12:30 p.m. EST, Bionano's stock price was down 13%.
Now what
Bionano expects to raise roughly $200 million via the sale of 33,333,350 shares of common stock at a price of $6 per share. It also gave underwriters the option to purchase (and subsequently sell) an additional 5 million shares at the same price. Bionano's stock sale is expected to close on Jan. 22.